Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Adenocarcinoma × Imiquimod × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Keratosis, Actinic 17 Condylomata Acuminata 3 Carcinoma, Basal Cell 3 Urinary Bladder Neoplasms 2 Non-Muscle Invasive Bladder Neoplasms 2 Keratosis 2 Glioblastoma 2 Warts 1 Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) 1 Virus Diseases 1 Sialorrhea 1 Sexually Transmitted Diseases 1 Papillomavirus Infections 1 Neoplasms 1 Neoplasm Metastasis 1 Melanoma 1 Lung Neoplasms 1 Glioma 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma in Situ 1 Atypical Squamous Cells of the Cervix 1 Adenocarcinoma 1

Interventions

Gemcitabine 22 Fluorouracil 12 Cisplatin 11 Carboplatin 11 Capecitabine 11 pembrolizumab 10 Pemetrexed 10 Paclitaxel 10 Oxaliplatin 10 130-nm albumin-bound paclitaxel 8 zolbetuximab 7 Leucovorin 7 trastuzumab deruxtecan 6 Ramucirumab 6 Albumin-Bound Paclitaxel 6 Nivolumab 4 Drug Therapy 4 Docetaxel 4 Bevacizumab 4 vandetanib 3 cemiplimab 3 Everolimus 3 EC145 3 tislelizumab 2 technetium 99m etarfolatide 2 spartalizumab 2 pralsetinib 2 osimertinib 2 nimotuzumab 2 napabucasin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02234921 2018-10-11

DRibble

UbiVac

Phase 1 Completed

Adenocarcinoma, Neoplasm Metastasis, Sialorrhea

Data powered by HemOnc (CC BY 4.0) Colophon ⚡